Evidence map›Paper›PMID 33813043›Full record

ReviewCurrent opinion in chemical biology2021

The ubiquitin proteoform problem.

Kirandeep K Deol, Eric R Strieter

Abstract readReview
In one paragraph

Review in Current opinion in chemical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. The Molecular Toolbox for Linkage Type-Specific Analysis of Ubiquitin Signaling.Chembiochem : a European journal of chemical biology · 2025
    Review
  6. Review
  7. Article
  8. Reading and Writing the Ubiquitin Code Using Genetic Code Expansion.Chembiochem : a European journal of chemical biology · 2024
    Review
  9. Article
  10. Article
  11. Quantitative Analysis of Diubiquitin Isomers Using Ion Mobility Mass Spectrometry.Journal of the American Society for Mass Spectrometry · 2023
    Article
  12. Review
  13. Site-specific ubiquitination: Deconstructing the degradation tag.Current opinion in structural biology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kirandeep K DeolDepartment of Chemistry, University of Massachusetts, Amherst, MA, 01003, USA.
Eric R StrieterDepartment of Chemistry, University of Massachusetts, Amherst, MA, 01003, USA; Department of Biochemistry and Molecular Biology, University of Massachusetts, Amherst, MA, 01003, USA.

Funding

Understanding the Function of Deubiquitinases Using Chemical Tools: Administrative SupplementR01GM110543 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI STRIETER, ERIC ROBERT · 2014 to 2022
$2.9M
NIGMS NIH HHS R01 GM110543
6 · The paper itself

Abstract

The diversity of ubiquitin modifications is immense. A protein can be monoubiquitylated, multi-monoubiquitylated, and polyubiquitylated with chains varying in size and shape. Ubiquitin itself can be adorned with other ubiquitin-like proteins and smaller functional groups. Considering different combinations of post-translational modifications can give rise to distinct biological outcomes, characterizing ubiquitylated proteoforms of a given protein is paramount. In this Opinion, we review recent advances in detecting and quantifying various ubiquitin proteoforms using mass spectrometry.

Indexed as

Binding SitesHumansLysineMass SpectrometryProtein ConformationProtein Processing, Post-TranslationalProteomeProteomicsSubstrate SpecificityUbiquitinUbiquitinationLysineProteomeUbiquitinBottom-up proteomicsMiddle-down proteomicsProteoformTop-down proteomicsUbiquitinUbiquitin chain

Identifiers

PMID33813043
PMCPMC8384647

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.